Mixed lineage kinase activity of indolocarbazole analogues

Chikara Murakata(Kyowa Kirin (Japan)), Robert L. Hudkins(State Street (United States)), Beth Ann McKenna, Teresa M. O’Kane, Masami Kaneko(Kyowa Kirin (Japan)), Mark A. Ator, Beth Ann Thomas, George Gessner(Brandywine Photonics (United States)), Joanne R. Mathiasen, Michael S. Saporito(Teva Pharmaceuticals (United States)), Thelma S. Angeles, Donna Bozyczko‐Coyne

Bioorganic & Medicinal Chemistry Letters

January 1, 2002

10.1016/s0960-894x(01)00690-4

Cited by 94

Related Papers

Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery

|ACS Chemical Neuroscience|2011|436

CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

|PubMed|2003|124

Neurotrophic 3,9-Bis[(alkylthio)methyl]- and -Bis(alkoxymethyl)-K-252a Derivatives

|Journal of Medicinal Chemistry|1997|120

Recent advances in targeting the fatty acid biosynthetic pathway using fatty acid synthase inhibitors

|Expert Opinion on Drug Discovery|2016|113

The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity

|Molecular Cancer Therapeutics|2007|112